Background: A 1995 meta analysis of chemotherapy in patients with advanced non-small cell carcinoma indicated clinical benefit from cisplatin based chemotherapy. Subsequent studies have aimed to increase the efficacy or decrease the toxicity of chemotherapy.
introduction
In 1995, a landmark meta-analysis of randomised clinical trials in patients with advanced and metastatic non-small cell lung cancer (NSCLC), compared chemotherapy to supportive care [1] . This showed that cisplatin-based chemotherapy resulted in increased patient survival and resulted in the widespread use of chemotherapy in patients with good performance status. New active drugs for patients with NSCLC have been introduced, which have further improved the outcome of chemotherapy. Further studies have been undertaken to decrease treatment toxicity and increase treatment options. These developments are discussed below for patients, through illustrative studies and meta-analyses.
doublet regimens
The NSCLC Collaborative Group meta-analysis compared chemotherapy to best supportive care and used individual and updated patient data from 1190 patients and 11 trials [1] . It established that cisplatin based chemotherapy prolonged patient survival with a hazard ratio of 0.73 and a P value of 0.001. (Table 1 ). This was in contrast to regimens based on alkylating agents, which had a detrimental effect on patient survival.
A series of drugs so-called third generation cytotoxics, were subsequently introduced for the treatment of NSCLC. The most prominent of these were docetaxel, gemcitabine, paclitaxel and vinorelbine. All the agents except for gemcitabine were active on the cell spindle. Gemcitabine however had a different mechanism of action and functioned as an anti-metabolite which was associated with prolonged cell uptake and cell potentiation [2] . Its activity as a single agent was first reported in 1994 [3] and it was subsequently shown to be active in association with cisplatin [4] .
The ECOG 1594 study was undertaken to compare different cytotoxic regimens [5] . The test regimens were cisplatingemcitabine, cisplatin-docetaxel and carboplatin-paclitaxel. The reference regimen in that study was cisplatin and Paclitaxel, given over 24 h. The study accrued 1167 patients. Overall, the median survival varied between 7.4 and 8.2 months, but none of the test arms resulted in increased survival rate, when compared to the reference arm. The most active of the test arms was the gemcitabine-cisplatinum combination which had a statistically significantly longer time to progression (4.5 compared to between 3.3 and 3.6 months in the reference and other regimens). The gemcitabine-cisplatin combination was also associated with a numerically higher 2-year survival rate of 15.7% compared to between 10.5% and 11.5% with the other regimens.
A meta-analysis of the gemcitabine combinations compared to non-gemcitabine combinations, was reported in 2005 [6] .
In 13 trials there were 4556 patients ( Table 2 ). This study showed that the median survival with gemcitabine-containing combinations was significantly increased with an overall absolute improvement in one year survival rate of 3.9% and a hazard ratio of 0.90. A subset analysis of this trial showed that when only third generation agents were combined with cisplatin, the overall survival tended to favour the gemcitabine containing regimens. The progression free survival remained statistically significantly better with the gemcitabine based regimens with a hazard ratio of 0.89. A sensitivity analysis of the meta-analysis done by excluding single agents, triplet agents and carboplatin all revealed a tendency in favour of the gemcitabine-based regimens.
single agents
Single agent therapy has been evaluated to maintain the efficacy of anti-cancer therapy while reducing the toxicity. However, in the studies of gemcitabine, docetaxel, paclitaxel and vinorelbine, in which these agents were compared to a doublet combination, there has been a statistically significantly better response rate and survival with the use of the agents when combined with a platin [7] [8] [9] [10] .
These findings were also confirmed in a meta-analysis (Table 3 ) [11] . There was an absolute gain in response rate from 13% to 26% in the use of two agents as opposed to one agent. There was also an increase in survival rate with the one year survival rate increasing from 30% to 35%. This was indeed associated with an increased toxicity which was statistically significant (Table 4 ). There was an increase in anaemia, neutropenia, thrombocytopenia, nephrotoxicity and neurotoxicity. Overall, however, the rate of toxicity remained moderate and there was no increase in infection.
triplet regimens
Attempts were made to improve the results of chemotherapy by the use of triplet combinations (Table 3) . A meta-analysis of the relevant randomised studies, showed an increase in the response rate overall from 23% to 31% which was statistically significant [11] . There was no gain in survival rate with the three agents. There was, however, an increase in toxicity with the 3 agents, as shown in Table 3 . The use of three agents resulted in an increase in anaemia, neutropenia, thrombocytopenia, infection and mucositis. Neurotoxicity and renal toxicity was similar in the two-and three-agent combinations.
carboplatin combinations
Regimens have been developed, in which cisplatin is replaced by carboplatin in order to improve the tolerability of the regimens. The activity and good tolerability of carboplatin was demonstrated in a Swedish study in which gemcitabine given on day 1 and 8 was compared to the same dose of gemcitabine and carboplatin given at an area under the curve of 5 on day 1 in a 3-weekly cycle. This study included 334 patients and 37% of the patients were over 70 years of age. This study showed a statistically significant increase in response rate from 12 to 30% and one-year survival rate from 32% to 41% with the use of carboplatin and gemcitabine. The combination was well tolerated with an incidence of grade 3 infection taking place in only 1% of patients.
The efficacy of carboplatin based doublets compared to standard chemotherapy regimens is also illustrated by the results of a London study [12] . In that study 422 patients with stage 3 B and 4 NSCLC were randomised to receive either the combination of mitomycin 3 mg/m 2 , ifosfamide 3 mg/m 2 and cisplatin 50 mg/m 2 all given on day 1 or gemcitabine at 1200 mg/m 2 on day 1 and 8 together with carboplatin at an area under the curve of 5 on day 1. A similar response rate of 41% was found in both arms of the study. However the median survival time 6.9 compared to 10.2 months and the one-year survival rate 28% compared to 38% were statistically significantly higher in carboplatin and gemcitabine combination.
A meta-analysis has been done to compare cisplatin and carboplatin-containing agents [13] . Overall there was a statistically significant increase in the response rate in the patients receiving cisplatin. There was no increase in survival with cisplatin. However, if the comparator arm was limited to the third generation agents, the survival favoured the use of cisplatin based combination chemotherapy (P = 0.039) ( Table 5 ). The use of cisplatin was, however, associated with significantly more nausea and vomiting. The use of carboplatin was associated with more thrombocytopenia, but this was not clinically significant. The treatment-related deaths were similar in both arms of the study.
non-platin combinations
Non-cisplatin containing regimens have been compared to cisplatin containing regimens in a series of trials. Gemcitabine has been a consistent feature of third generation non-platin containing regimens, in part because of its different mechanism of action. There has been a recent meta-analysis of platin versus non-platin containing regimens (see Table 6 [1]). There were 7633 patients in 37 trials. Both the response rate and the one year survival rate favoured the use of platin containing agents, both were statistically significant. However if the nonplatin containing regimens were limited to third generation agents, there were 3204 patients in 14 trials. The response rate remained higher in the platinum containing regimens, with an odds ratio of 1.17 and a p value of 0.042. The one-year survival rate, however, was not statistically significant with an odds ratio of 1.11 and a one-year survival rate of 36% compared to 35%. Toxicity was worse in the cisplatin containing arm -there was more anaemia, neutropenia, thrombocytopenia, nephrotoxicity as well as nausea and vomiting. Neurotoxicity and treatment deaths were not, however, statistically significantly different in the two groups.
optimum duration of therapy
Optimum duration of therapy has been evaluated in a series of studies [19] [20] [21] . There is no gain increased when cycles of chemotherapy were compared in 3-6 cycles or when treating patients until they have progression of disease. Increased toxicity such as peripheral neurotoxicity, fatigue and anaemia has however been observed in these studies with prolongation of therapy.
conclusion
Randomised clinical trials and meta-analyses are the best levels of evidence that we have in clinical medicine. The best form of meta-analysis depends on obtaining individual patient data (IPD) from studies, as was done in the original meta analysis to establish platin based chemotherapy in the treatment of patients of NSCLC. IPD allows checks to be done on the following of an intent-to-treat analysis: the randomisation process, the integrity of data, as well as allowing for the updating of data. The analysis will also check the heterogeneity of the population so that prognostic factors are evenly balanced and the statistical analysis will be comprehensive. This process is, however very time consuming and can take from 1-5 years and is associated with a high cost. More frequently, the metaanalysis will be based on abstracted or summary data. Many Table 3 . Meta analysis of 1 compared to 2 as well as 2 compared to 3 chemotherapy agents in patients with advanced NSCLC [11] Odds ratio (to favour 2 agents) cross-checks will therefore not be able to be done -for example patients may be excluded from the analysis and regarded as ineligible because of early progressive disease. The analysis will be done at a point in time, for example, the one year survival rates. This approach is, however, much quicker and cheaper. This should therefore be regarded as a first step towards the performance of an individual patient data meta-analysis. The findings in these studies are compatible with and support the current ASCO guideline. First line chemotherapy given to patients with advanced NSCLC should be two-drug combination regimen. Non-platin containing regimens may be used as an alternative to platinum based regimens in the first line. Further progress in treatment of patients with advanced or metastatic NSCLC can be expected from the increased use of biological agents.
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